TP63 and neoplasm: Treatment with siRNAs targeting TP63 (siTP63) or ATP1B3 (siATP1B3) significantly suppressed tumor-promoting functions of HNSCC cells, including cell viability, tumor sphere formation, migration, and invasion (Fig. 2g, h, I and Supplementary Fig. 3).